|
|
Blood, 15 August 2006, Vol. 108, No. 4, pp. 1313-1319.
Prepublished online as a Blood First Edition Paper on April 18, 2006; DOI 10.1182/blood-2005-11-011320.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15
Claire L. Sutherland,
Brian Rabinovich,
N. Jan Chalupny,
Pierre Brawand,
Robert Miller, and
David Cosman
From the Department of Oncology, Amgen, Seattle, WA.
ULBPs are human ligands for NKG2D, an activating receptor expressed on natural killer (NK) cells, NK1.1+ T cells, and T cells. ULBPs are expressed by a variety of leukemias, carcinomas, melanomas, and tumor cell lines. ULBP expression correlates with improved survival in cancer patients, however, the nature of the immune response that ULBPs elicit is not well understood. We report that ectopic expression of ULBP1 or ULBP2 on murine EL4 or RMA tumor cells elicits potent antitumor responses in syngeneic C57BL/6 and SCID mice. Although binding of ULBP3 to murine NKG2D could not be demonstrated in vitro, ULBP3 can also stimulate antitumor responses, suggesting that ULBP3 binds to murine NKG2D or possibly another receptor in vivo. ULBP expression was found to recruit NK cells, NK1.1+ T cells, and T cells to the tumor. IL-15 was found to strongly enhance the immune response directed against ULBP-expressing tumors. Tumors can evade NKG2D immunity by down-regulating expression of NKG2D. Our data suggest that IL-15 may be useful for overcoming this tumor-evasion strategy. Together, these results demonstrate that ULBP expression can elicit a potent immune response and suggest that ULBPs, alone or in combination with IL-15, can be exploited for antitumor therapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Le Maux Chansac, D. Misse, C. Richon, I. Vergnon, M. Kubin, J.-C. Soria, A. Moretta, S. Chouaib, and F. Mami-Chouaib
Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway
Int. Immunol.,
July 1, 2008;
20(7):
801 - 810.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Cao, X. Xi, Z. Wang, L. Dong, Z. Hao, L. Cui, C. Ma, and W. He
Four novel ULBP splice variants are ligands for human NKG2D
Int. Immunol.,
June 10, 2008;
(2008)
dxn057v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Clayton, J. P. Mitchell, J. Court, S. Linnane, M. D. Mason, and Z. Tabi
Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
J. Immunol.,
June 1, 2008;
180(11):
7249 - 7258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al.
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities
Blood,
February 1, 2008;
111(3):
1428 - 1436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Guan, M. Moretto, D. J. Bzik, J. Gigley, and I. A. Khan
NK Cells Enhance Dendritic Cell Response against Parasite Antigens via NKG2D Pathway
J. Immunol.,
July 1, 2007;
179(1):
590 - 596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Cao, X. Xi, Z. Hao, W. Li, Y. Kong, L. Cui, C. Ma, D. Ba, and W. He
RAET1E2, a Soluble Isoform of the UL16-binding Protein RAET1E Produced by Tumor Cells, Inhibits NKG2D-mediated NK Cytotoxicity
J. Biol. Chem.,
June 29, 2007;
282(26):
18922 - 18928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lopez-Soto, A. Quinones-Lombrana, R. Lopez-Arbesu, C. Lopez-Larrea, and S. Gonzalez
Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor
J. Biol. Chem.,
October 13, 2006;
281(41):
30419 - 30430.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
